Navigation Links
Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention
Date:5/13/2009

PRINCETON, N.J., May 13 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the 2009 BIO International Convention in Atlanta. Mr. Jackson will provide a corporate overview and an update on the company's progress with two ongoing Phase 2 clinical trials of CPX-351 in newly diagnosed acute myeloid leukemia (AML) patients and first-relapse AML patients. The presentation will be held on Wednesday, May 20, 2009 at 3:40pm EDT in Room 311 of the Georgia World Congress Center.

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
2. Celator(R) Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
3. Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
4. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
5. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
6. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
7. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
8. Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference
9. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
10. Vion Pharmaceuticals Reports 2009 First Quarter Results
11. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... a one-stop portal for all the knowledge resources, including white papers, guides, handbooks, ... and more. , To access more than 9,000 documents, webinars and videos ...
(Date:12/6/2016)... ... ... Keeping Gift Season Safe, In a season stacked with gift-giving opportunities, it's important ... This is the idea behind Safe Toys and Gifts Month, which sets aside December ... gifts for children. For companies that produce goods that fall into this category, it's ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has announced the ... providing occupational safety and health training to public sector employees. , “The primary ...
(Date:12/5/2016)... , ... December 05, 2016 , ... "FCPX Overlay Glare ... but natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - ... media to create an organic spectrum of lights that simulates the look of a ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... been featured in SuperbCrew magazine, a leading online tech news platform connecting technology ... now featured on SuperbCrew.com, explores the state of enterprise mobility security today, and ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016 Spain Glaucoma Surgery Devices ... report, "Spain Glaucoma Surgery Devices Market Outlook to 2022", ... Devices market. The report provides value, in millions of ... within market segements - Canaloplasty Micro Catheters and Glaucoma ... and distribution shares data for each of these market ...
(Date:12/5/2016)... Special purpose needles are used in target specific ... cells from organs or lumps and are available in the ... market for special purpose needles is showing a steady growth ... the global special purpose needles market is projected to expand ... and is expected to be valued at US$ 17,261.5 million ...
(Date:12/5/2016)... and BOCA RATON, Fla. ... Institute for the Commercialization of Public Research ... finalized a funding agreement SegAna, LLC, an ... at University of Central Florida. The Florida Institute ... and bridges early funding gaps for companies spinning ...
Breaking Medicine Technology: